BUZZ — Grail rises as TD Cowen more than doubles PT on FDA, Medicare optimism

* Grail shares rise over 2% to $140.53 * TD Cowen hikes PT on cancer test maker to $180 from $88 — implying a 31% upside to last close; keeps 'buy' rating * Brokerage raises FDA approval chance for GRAL's Galleri early cancer-detection test to 95% from 75% after FDA advisory committee meeting, expects decision in Q127 * Expects favorable Medicare coverage decision in H128 * 5 of 12 brokerages rate GRAL "buy" or above, 7 "hold"; median PT: $120 - data compiled * Including session's moves, stock up ~64% YTD (Reporting by Miraanta Lowrance in Bengaluru) ((miraanta.lowrance@thomsonreuters.com)